January 1994 in “Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics” Both VEPA and ML-Y1 treatments are not effective enough for elderly non-Hodgkin's lymphoma patients.
January 2006 in “Zhongguo yaoke daxue xuebao” The method accurately measures vinflunine in dog plasma.
2 citations
,
September 2021 in “Human Psychopharmacology: Clinical and Experimental” Valproate can cause hair problems, but there are ways to manage them.
January 2007 in “Zhōnghuá yàoxué zázhì” The method effectively showed that the two exemestane preparations are bioequivalent.
4 citations
,
January 2018 in “General Physiology and Biophysics” The steroids allopregnanolone and allotetrahydrodeoxycorticosteron worsened absence seizures in rats.
December 2025 in “Pharmaceutics” EV-based drug delivery shows promise but faces challenges in standardization and scalability.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
1 citations
,
March 2020 in “Journal of Pharmacological Sciences” Benzothiazepines like diltiazem reduce anxiety in mice by making neurosteroids.
GV-350 improves hair growth and quality of life in iron-deficient women without side effects.
11 citations
,
February 2007 in “Journal of Child and Adolescent Psychiatric Nursing” Combining mood stabilizers with antipsychotics is more effective for treating children with bipolar disorder than using mood stabilizers alone.
December 2024 in “PubMed” 8 citations
,
October 2019 in “The Journal of surgical research/Journal of surgical research” Sodium valproate helps skin healing by affecting GABA and histone deacetylase.
16 citations
,
October 2004 in “Acta dermato-venereologica” Two people lost a lot of hair because of epilepsy drugs, but their hair grew back after changing medication.
1 citations
,
April 2013 in “PubMed” February 2026 in “Biomaterials” BOOST is a promising, easy-to-use treatment for diabetic foot ulcers that improves healing by reducing inflammation and promoting blood vessel growth.
January 2017 in “SHILAP Revista de lepidopterología” Agomelatine might help reduce hair loss caused by valproate.
20 citations
,
August 1981 in “Developmental Medicine & Child Neurology” 13 citations
,
June 1981 in “Developmental Medicine & Child Neurology” September 2025 in “Bioengineering” The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.
June 2021 in “Psychiatria Danubina” The antidepressant escitalopram likely caused hair loss in a patient.
13 citations
,
January 2007 in “Epilepsia” Valproic acid can cause reversible hair curling and persistent hair thinning.
24 citations
,
January 2007 in “The FASEB Journal” Neurosteroid withdrawal increases seizure frequency in a rat model of catamenial epilepsy.
Different oral anticoagulants cause various non-bleeding side effects, so careful monitoring is needed.
65 citations
,
July 2013 in “International Clinical Psychopharmacology” Mood stabilizers like lithium and anticonvulsants have side effects that can lead to patients stopping their medication, and managing these effects is important for treatment adherence.
3 citations
,
October 2010 in “Epilepsy Currents” Altered metabolism can help control seizures by changing brain signaling and energy use, suggesting new treatments for epilepsy.
June 2021 in “Research Square (Research Square)” Sudanese epilepsy patients often experience hair loss from anti-epileptic drugs but continue their medication regardless of cosmetic side effects.
19 citations
,
September 2020 in “Pharmaceutics” Sodium Valproate nanospanlastics could be a safe and effective treatment for Androgenic Alopecia, with fewer side effects than minoxidil.
1 citations
,
January 2018 in “Journal of Neurology Research” A young man had rare serious side effects from an epilepsy drug, leading to stopping the drug.
3 citations
,
January 1977 in “Electroencephalography and Clinical Neurophysiology” November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.